{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:03:08Z","timestamp":1791370988739,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970044"],"award-info":[{"award-number":["31970044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32370805"],"award-info":[{"award-number":["32370805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jmgm.2025.109052","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:19:43Z","timestamp":1744507183000},"page":"109052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification of novel inhibitors targeting EGFR L858R\/T790M\/C797S against NSCLC by molecular docking, MD simulation, and DFT approaches"],"prefix":"10.1016","volume":"138","author":[{"given":"Chaochun","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keli","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmgm.2025.109052_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114492","article-title":"Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors","volume":"238","author":"Ding","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"5676","key":"10.1016\/j.jmgm.2025.109052_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science (Am. Associat. Adv. Sci.)"},{"issue":"7","key":"10.1016\/j.jmgm.2025.109052_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of t790m-positive cancers with a third-generation EGFR inhibitor","volume":"5","author":"Piotrowska","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jmgm.2025.109052_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acsmedchemlett.5b00475","article-title":"Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer","volume":"7","author":"Engel","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.jmgm.2025.109052_bib5","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jmgm.2025.109052_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jmgm.2025.109052_bib7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1535-7163.MCT-11-0750","article-title":"The EGFR t790m mutation in acquired resistance to an irreversible second-generation EGFR inhibitor","volume":"11","author":"Kim","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.jmgm.2025.109052_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","article-title":"Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers","volume":"11","author":"Yu","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8","key":"10.1016\/j.jmgm.2025.109052_bib9","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR -mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jmgm.2025.109052_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmgm.2025.109052_bib11","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jmgm.2025.109052_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jmgm.2025.109052_bib13","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7605","key":"10.1016\/j.jmgm.2025.109052_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(t790m) and EGFR(c797s) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jmgm.2025.109052_bib15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes osimertinib-resistant EGFR-del19\/t790m\/c797s mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.jmgm.2025.109052_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113786","article-title":"A sulfonyl fluoride derivative inhibits EGFRl858r\/t790m\/c797s by covalent modification of the catalytic lysine","volume":"225","author":"Ferlenghi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmgm.2025.109052_bib17","doi-asserted-by":"crossref","unstructured":"Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01169.","DOI":"10.1021\/acs.jmedchem.9b01169"},{"key":"10.1016\/j.jmgm.2025.109052_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115865","article-title":"Modification of osimertinib to discover new potent EGFRC797s-TK inhibitors","volume":"261","author":"Xi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmgm.2025.109052_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125466","article-title":"Corrigendum to \u201cPF543-like compound, a promising sphingosine kinase 1 inhibitor: structure-based virtual screening and molecular dynamic simulation approaches\u201d","volume":"245","author":"Shahwan","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jmgm.2025.109052_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124169","article-title":"Identification of RdRp inhibitors against SARS-CoV-2 through e-pharmacophore-based virtual screening, molecular docking and MD simulations approaches","volume":"237","author":"Rehman","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jmgm.2025.109052_bib21","unstructured":"A.H.V.D. Lindahl, GROMACS 2020.7 source code (Version, 2023-12-01 20:21:00, 2022. https:\/\/zenodo.org\/records\/5938877."},{"issue":"11","key":"10.1016\/j.jmgm.2025.109052_bib22","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes osimertinib-resistant EGFR-del19\/t790m\/c797s mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.jmgm.2025.109052_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17020246","article-title":"Systems pharmacology in small molecular drug discovery","volume":"17","author":"Zhou","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"69","key":"10.1016\/j.jmgm.2025.109052_bib24","doi-asserted-by":"crossref","first-page":"39477","DOI":"10.1039\/C8RA08198K","article-title":"Multiple 3d-QSAR modeling, e-pharmacophore, molecular docking, and in vitro study to explore novel AChE inhibitors","volume":"8","author":"Jana","year":"2018","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.jmgm.2025.109052_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.jmgm.2025.109052_bib26","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"PkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jmgm.2025.109052_bib27","first-page":"388","article-title":"Identification of potential hit compounds for dengue virus NS2b\/NS3 protease inhibitors by combining virtual screening and binding free energy calculations","volume":"30","author":"Wichapong","year":"2013","journal-title":"Trop. Biomed."},{"issue":"8","key":"10.1016\/j.jmgm.2025.109052_bib28","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"Ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"issue":"9","key":"10.1016\/j.jmgm.2025.109052_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2025.109052_bib30","series-title":"Gaussian 16 Rev. C.01 (Version, 2023-04-17 09:43:00","author":"Frisch","year":"2016"},{"issue":"5","key":"10.1016\/j.jmgm.2025.109052_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.jmgm.2025.109052_bib32","series-title":"Sobtop 1.0(dev3.1","author":"Lu","year":"2023"},{"issue":"10","key":"10.1016\/j.jmgm.2025.109052_bib33","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"Gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.jmgm.2025.109052_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/bs.pmch.2021.01.004","article-title":"Use of molecular docking computational tools in drug discovery","volume":"60","author":"Stanzione","year":"2021","journal-title":"Prog. Med. Chem."},{"issue":"8","key":"10.1016\/j.jmgm.2025.109052_bib35","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.bmc.2018.02.029","article-title":"Discovery of selective EGFR modulator to inhibit l858r\/t790m double mutants bearing a n-9-diphenyl-9h-purin-2-amine scaffold","volume":"26","author":"Hu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"23\u201324","key":"10.1016\/j.jmgm.2025.109052_bib36","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1016\/j.bmc.2018.10.018","article-title":"Design, synthesis and evaluation of the osimertinib analogue (c-005) as potent EGFR inhibitor against NSCLC","volume":"26","author":"Zhou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"23\u201324","key":"10.1016\/j.jmgm.2025.109052_bib37","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1016\/j.bmc.2018.11.009","article-title":"The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR t790m\/l858r inhibitors for NSCLC","volume":"26","author":"Chen","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.jmgm.2025.109052_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-2836(84)90231-6","article-title":"Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect","volume":"178","author":"Richmond","year":"1984","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.jmgm.2025.109052_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1134\/S0026893308040195","article-title":"Radius of gyration as an indicator of protein structure compactness","volume":"42","author":"Lobanov","year":"2008","journal-title":"Mol. Biol."},{"issue":"6","key":"10.1016\/j.jmgm.2025.109052_bib40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2014.10.002","article-title":"Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation","volume":"4","author":"Fang","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jmgm.2025.109052_bib41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jmgm.2016.11.012","article-title":"Structural dynamics of casein kinase i (CKI) from malarial parasite plasmodium falciparum (isolate 3d7): insights from theoretical modelling and molecular simulations","volume":"71","author":"Dehury","year":"2017","journal-title":"J. Mol. Graph."},{"issue":"8","key":"10.1016\/j.jmgm.2025.109052_bib42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jmgm.2009.01.006","article-title":"Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case","volume":"27","author":"Papaleo","year":"2009","journal-title":"J. Mol. Graph."},{"issue":"2","key":"10.1016\/j.jmgm.2025.109052_bib43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ijms17020144","article-title":"Insights into protein-ligand interactions: mechanisms, models, and methods","volume":"17","author":"Du","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmgm.2025.109052_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127379","article-title":"Discovery of druggable potent inhibitors of serine proteases and farnesoid x receptor by ligand-based virtual screening to obstruct SARS-CoV-2","volume":"253","author":"Zaib","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.jmgm.2025.109052_bib45","first-page":"231","article-title":"Interaction region indicator: a simple real space function clearly revealing both chemical bonds and weak interactions\u2217\u2217","volume":"1","author":"Lu","year":"2021","journal-title":"Chem. Mater."}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326325001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326325001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:47:13Z","timestamp":1746103633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326325001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"alternative-id":["S1093326325001123"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2025.109052","relation":{},"ISSN":["1093-3263"],"issn-type":[{"value":"1093-3263","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel inhibitors targeting EGFR L858R\/T790M\/C797S against NSCLC by molecular docking, MD simulation, and DFT approaches","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2025.109052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109052"}}